Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | HTR1E | P28566 | 1/20 | 0.45 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | PHGDH | O43175 | 1/20 | 0.43 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1769201 | 0.89 | NPSR1 (0.50) | L3MBTL1HDAC1MAPK1NPSR1MAPT | |
| SCHEMBL3224174 | 0.85 | NPSR1 (0.55) | L3MBTL1HDAC1NPSR1MAPTHTR1E | |
| SCHEMBL3900070 | 0.85 | AKR1C1 (0.59) | L3MBTL1NPSR1MAPTHTR1ES1PR3 | |
| SCHEMBL3903075 | 0.82 | L3MBTL1 (0.58) | L3MBTL1HDAC1SMN1; SMN2MAPK1NPSR1 | |
| SCHEMBL28625648 | 0.82 | L3MBTL1 (0.55) | L3MBTL1HDAC1SMN1; SMN2MAPK1NPSR1 | |
| SCHEMBL16423511 | 0.82 | L3MBTL1 (0.65) | L3MBTL1HDAC1SMN1; SMN2MAPK1NPSR1 | |
| SCHEMBL16423615 | 0.79 | LMNA (0.58) | L3MBTL1HDAC1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL23671577 | 0.79 | L3MBTL1 (0.48) | L3MBTL1HDAC1SMN1; SMN2MAPK1MAPT | |
| SCHEMBL1627580 | 0.78 | AKR1C1 (0.68) | L3MBTL1HDAC1SMN1; SMN2MAPK1NPSR1 | |
| SCHEMBL166581 | 0.77 | APP (0.50) | HDAC1NPSR1MAPTALDH1A1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220073485-A1 | Functionalised Amine Derivatives as IL-17 Modulators | UCB BIOPHARMA SRL (SOCIETE A RESPONSABILITE LIMITEE) (BE) | 2022-03-10 | — | — | US | disclosed |
| EP-3894003-A1 | FUNCTIONALISED AMINE DERIVATIVES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2021-10-20 | — | — | EP | disclosed |
| CN-113260418-A | Functionalized amine derivatives as IL-17 modulators | UCB生物制药有限责任公司 | 2021-08-13 | — | — | CN | disclosed |
| WO-2020120141-A1 | FUNCTIONALISED AMINE DERIVATIVES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2020-06-18 | — | — | WO | disclosed |
| US-9394289-B2 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2016-07-19 | — | — | US | disclosed |
| US-9394289-B2 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2016-07-19 | — | — | US | disclosed |
| EP-2016070-B1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-13 | — | — | EP | disclosed |
| EP-2016070-B1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-13 | — | — | EP | disclosed |
| US-9187453-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-11-17 | — | — | US | disclosed |
| CN-101472914-B | C-FMS kinase inhibitors | JANSSEN PHARMACEUTICA NV | 2015-05-20 | — | — | CN | disclosed |
| US-20140378457-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2014-12-25 | — | — | US | disclosed |
| US-20140378457-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2014-12-25 | — | — | US | disclosed |
| US-8859602-B2 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-14 | — | — | US | disclosed |
| US-8859602-B2 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-14 | — | — | US | disclosed |
| US-8859602-B2 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-14 | — | — | US | disclosed |
| EP-2016070-A1 | INHIBITORS OF C-FMS KINASE | Janssen Pharmaceutica, N.V. (BE) | 2009-01-21 | — | — | EP | disclosed |
| WO-2007124319-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-01 | — | — | WO | disclosed |
| US-20070249680-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-10-25 | — | — | US | disclosed |
| US-20070249680-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-10-25 | — | — | US | disclosed |
| US-20070249680-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378457-A1 | INHIBITORS OF C-FMS KINASE | MUSK, FRK, FES | L3MBTL1 1001/4885HDAC1 1847/4885SMN1; SMN2 2358/4885 |
| US-20220073485-A1 | Functionalised Amine Derivatives as IL-17 Modulators | IL17A, IL15, IL2 | L3MBTL1 4791/4885HDAC1 286/4885SMN1; SMN2 2374/4885 |
| US-20070249680-A1 | INHIBITORS OF C-FMS KINASE | MUSK, FRK, FES | L3MBTL1 1001/4885HDAC1 1847/4885SMN1; SMN2 2358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.